Novavax Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercialising next-generation vaccines for serious infectious diseases, announced on Monday that it has named Denny Kim, M.D., MPH as its new senior vice president, chief safety officer and head of Global Vaccine Safety.
Dr Kim is to report to Filip Dubovsky, M.D., MPH, FAAP, executive vice president and chief medical officer.
Dr Kim has around two decades of infectious disease, clinical trial and safety experience. He has served at Johnson & Johnson, where he was part of the office of the chief medical officer. He built and headed the global Patient Safety and Pharmacovigilance function at Horizon Pharma, developed a new safety function within Takeda's Vaccine Business Unit, and held the position of therapeutic area safety head at both Takeda and Astellas.
Poolbeg PHarma plc receives notice of allowance for POLB 001 patent
RedHill Biopharma secures USPTO Patent for Talicia, extending protection through 2034
Micron Biomedical names new scientific advisor to CEO
Quanterix partners with leading health networks for Alzheimer's diagnosis advancements
Precision BioSciences reports FDA pre-IND feedback for PBGENE-HBV
VBI to sell manufacturing capabilities and enter new license agreement with Brii Biosciences
Ondine Biomedical's Steriwave shows promise in nasal pathogen reduction
BioSenic expands patent coverage for ATO therapeutic platform
PacBio unveils Nanobind PanDNA kit for enhanced DNA extraction solutions
Sequentify receives funding from Israel Innovation Authority
INOVIO plans BLA submission for INO-3107 as RRP treatment
ImmunityBio secures USD320m investment from Oberland Capital
Poolbeg Pharma prioritises promising RSV drug candidates identified through AI-led analysis
GHIT fund invests JPY500m in antimalarial drug clinical trial